Option Therapeutics

Company snapshot

OYE Therapeutics is a clinical stage pharmaceutical development company. We are focused on bringing innovation to market that offers a positive return on investment in the form of improved safety, efficacy, equity, outcomes, and cost savings.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Option Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Option Therapeutics.

1. Jun 5, 2026 Clinical update

   Intravenous Immunoglobulin — Phase 3

2. Mar 7, 2023 Patent grant

   Compositions in support of health and mental accuity

3. Nov 6, 2018 Patent grant

   Highly branched alpha-D-glucans

4. Mar 22, 2016 Patent grant

   Targeted cytokine for treatment of musculoskeletal diseases

5. Apr 1, 2014 Patent grant

   Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases

View all clinical trial activity →

• What is Option Therapeutics?

  OYE Therapeutics is a pharma organization headquartered in CARSON CITY, NV, USA. It trades on NYSE under ticker OPTN. Primary therapeutic focus areas include Autoimmune Epilepsy. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 10 patent record(s) to this entity

• Is Option Therapeutics publicly traded?

  Yes. Option Therapeutics is listed with ticker OPTN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Option Therapeutics develop or market?

  We link 1 drug profile(s) where Option Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/option-therapeutics#company-drugs.

• What are the latest developments for Option Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Option Therapeutics focus on?

  Option Therapeutics focuses on Autoimmune Epilepsy based on our analysis of their pipeline programs and drug development activities.